Zobrazeno 1 - 10
of 44
pro vyhledávání: '"F. Crouwel"'
Publikováno v:
Journal of Pharmaceutical Policy and Practice, Vol 13, Iss 1 (2020)
Drug repositioning is the scientific strategy of investigating existing drugs for additional clinical indications. The advantages of drug repositioning are that it benefits patients and that it adds new indications to existing drugs for lower costs c
Externí odkaz:
https://doaj.org/article/e16e237bbb4e40a8852f43f41c583754
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Journal of Pharmaceutical Policy and Practice, Vol 13, Iss 1, Pp 1-9 (2020)
Bayoumy, A B, De Boer, N K H, Ansari, A R, Crouwel, F & Mulder, C J J 2020, ' Unrealized potential of drug repositioning in europe during COVID-19 and beyond : A physcian's perspective ', Journal of pharmaceutical policy and practice, vol. 13, no. 1, 45 . https://doi.org/10.1186/s40545-020-00249-9
Journal of Pharmaceutical Policy and Practice
Bayoumy, A B, De Boer, N K H, Ansari, A R, Crouwel, F & Mulder, C J J 2020, ' Unrealized potential of drug repositioning in europe during COVID-19 and beyond : A physcian's perspective ', Journal of pharmaceutical policy and practice, vol. 13, no. 1, 45 . https://doi.org/10.1186/s40545-020-00249-9
Journal of Pharmaceutical Policy and Practice
Drug repositioning is the scientific strategy of investigating existing drugs for additional clinical indications. The advantages of drug repositioning are that it benefits patients and that it adds new indications to existing drugs for lower costs c
Autor:
E H J Savelkoul, M H J Maas, A R Bourgonje, F Crouwel, V B C Biemans, N den Broeder, M G V M Russel, T E H Römkens, N K de Boer, G Dijkstra, F Hoentjen
Publikováno v:
Savelkoul, E H J, Maas, M H J, Bourgonje, A R, Crouwel, F, Biemans, V B C, den Broeder, N, Russel, M G V M, Römkens, T E H, de Boer, N K, Dijkstra, G & Hoentjen, F 2022, ' Favourable Tolerability and Drug Survival of Tioguanine Versus Methotrexate After Failure of Conventional Thiopurines in Crohn's Disease ', Journal of Crohn's & colitis, vol. 16, no. 9, pp. 1372-1379 . https://doi.org/10.1093/ecco-jcc/jjac044
Journal of Crohn's and Colitis, 16, 1372-1379
Journal of Crohn's and Colitis, 16(9). Oxford University Press
Journal of Crohn's & colitis, 16(9), 1372-1379. Elsevier
Journal of Crohn's and Colitis, 16, 9, pp. 1372-1379
Journal of Crohn's and Colitis, 16, 1372-1379
Journal of Crohn's and Colitis, 16(9). Oxford University Press
Journal of Crohn's & colitis, 16(9), 1372-1379. Elsevier
Journal of Crohn's and Colitis, 16, 9, pp. 1372-1379
Background and Aims Both methotrexate and tioguanine can be considered as treatment options in patients with Crohn’s disease after failure of conventional thiopurines. This study aimed to compare tolerability and drug survival of methotrexate and t
P592 Effectiveness and safety of thioguanine in thiopurine-naïve Inflammatory Bowel Disease patients
Autor:
F Crouwel, A B Bayoumy, C J J Mulder, J H C Peters, P J Boekema, L J J Derijks, S Y De Boer, P C van de Meeberg, I Ahmad, H J C Buiter, N K de Boer
Publikováno v:
Journal of Crohn's and Colitis. 16:i529-i529
Background Currently thioguanine is considered as off-label rescue therapy for Inflammatory Bowel Disease (IBD) after conventional thiopurine failure. This study aimed to determine the safety, effectiveness and 12-month drug tolerability of thioguani
Autor:
Maurice G. Russel, N de Boer, Gerard Dijkstra, A Bourgonje, Frank Hoentjen, M Maas, F Crouwel, Edo Savelkoul, Tessa E H Römkens
Publikováno v:
Journal of Crohn's and Colitis. 15:S390-S391
Background Both methotrexate (MTX) and tioguanine (TG) can be considered as viable treatment options before initiating biological therapy following failure of conventional thiopurines for Crohn’s disease. It is unclear how safety and effectiveness
Autor:
M A de Boer, H J C Buiter, Colitis (Icc), F Crouwel, M Simsek, Chris J. J. Mulder, N K De Boer
Publikováno v:
Journal of Crohn's and Colitis. 15:S354-S355
Background Azathioprine and mercaptopurine exposure during conception and pregnancy has been considered safe in patients with inflammatory bowel disease (IBD). Its use is not associated with a higher risk of preterm birth or low birthweight. Data on
Publikováno v:
Journal of Crohn's and Colitis. 15:S510-S510
Background For measurement of fecal calprotectin (FC) a stool sample is sent to the laboratory, where calprotectin is extracted and determined. With the CALiaGold (CG) tube, especially designed for home sampling, this labor-intensive extraction proce